Sharescart Research Club logo

Key Financials Snapshot

TTM · Standalone · ₹ in Cr
Market Cap
₹30 Cr.
Stock P/E
-20.2
P/B
1.1
Current Price
₹81
Book Value
₹ 73.4
Face Value
10
52W High
₹189
52W Low
₹ 76.3
Dividend Yield
0%

Centenial Surgical Overview

Here's a structured overview of Centenial Surgical Suture Ltd. based on the provided information:

Centenial Surgical Suture Ltd.

1. Business Overview

Centenial Surgical Suture Ltd. is an Indian company operating in the Medical Equipment/Supplies/Accessories sector. Based on its name, the company's core business involves the manufacturing and/or distribution of surgical sutures. It likely operates on a Business-to-Business (B2B) model, supplying its products to hospitals, surgical centers, clinics, and potentially other medical institutions and distributors across India. The company generates revenue through the direct sale of these essential medical consumables required for surgical procedures and wound closure.

2. Key Segments / Revenue Mix

Given the company's name, its primary and dominant business segment is the production and sale of surgical sutures. While it may potentially offer related wound care products or other surgical disposables, surgical sutures are expected to constitute the vast majority of its revenue. Specific segment contribution percentages are not available from the provided information.

3. Industry & Positioning

The company operates within the broader Indian medical equipment and supplies industry, specifically targeting the surgical disposables market. This industry is characterized by a mix of large multinational corporations and numerous domestic manufacturers. The market for surgical sutures is generally competitive, with players competing on product quality, material types (e.g., absorbable vs. non-absorbable, monofilament vs. braided), price, regulatory approvals, and distribution reach. Centenial Surgical Suture Ltd. likely positions itself by leveraging domestic manufacturing, potentially offering competitive pricing, and building a distribution network within India to serve a range of healthcare providers.

4. Competitive Advantage (Moat)

Without specific company details, potential competitive advantages for Centenial Surgical Suture Ltd. could include:

Distribution Network: A well-established and efficient sales and distribution network across India, allowing broad access to hospitals and surgeons.

Cost Efficiency: As a domestic manufacturer, it might benefit from lower production costs compared to imports, enabling competitive pricing.

Brand Reputation: A long-standing reputation for quality and reliability among surgeons and procurement departments can foster loyalty, given the critical nature of surgical products.

Regulatory Expertise: Proficiency in navigating India's medical device regulations for quick product approvals and market access.

High switching costs are less typical for standard sutures, though surgeons' familiarity with specific brands can create some inertia.

5. Growth Drivers

Healthcare Infrastructure Expansion: The ongoing growth and modernization of hospitals and surgical facilities in India.

Increasing Surgical Procedures: Rising prevalence of chronic diseases, increasing access to healthcare, and a growing population leading to a higher volume of surgical interventions.

Growing Healthcare Expenditure: Continued increase in public and private spending on healthcare across India.

"Make in India" Initiative: Government policies promoting domestic manufacturing could provide a favorable operating environment and reduce import dependency.

Export Opportunities: Potential to expand sales to international markets, particularly in developing economies.

6. Risks

Intense Competition: Fierce competition from both domestic players and larger multinational companies, leading to pricing pressure and margin erosion.

Regulatory Changes: Evolving medical device regulations in India could impose higher compliance costs or restrict market access for certain products.

Supply Chain Volatility: Dependence on raw material availability and pricing, which can be subject to global supply chain disruptions.

Product Liability: Risk of legal claims related to product quality or performance in a critical application like surgery.

Technological Obsolescence: Potential for new wound closure technologies or materials to emerge, requiring continuous R&D investment.

Price Sensitivity: Hospitals and government procurement bodies often prioritize cost-effectiveness, impacting profit margins.

7. Management & Ownership

As is common for many Indian companies, Centenial Surgical Suture Ltd. is likely promoter-driven, with the founding family or group holding a significant stake and strategic control. Management quality would be critical in navigating the complex regulatory landscape, managing production, and expanding market reach. Given its listed status, there would be public shareholders alongside the promoters.

8. Outlook

Centenial Surgical Suture Ltd. operates in a fundamentally growing market driven by India's expanding healthcare needs. The bull case suggests the company is well-positioned to capitalize on increasing surgical volumes, potential for 'Make in India' tailwinds, and expanding its distribution network. Its focus on a critical consumable product offers a stable demand base. The bear case highlights significant competitive pressures from established domestic and international players, potential for pricing wars, and the need for continuous product innovation and quality control in a highly regulated environment. Regulatory shifts or disruptions in the supply chain for raw materials could also pose challenges. Its success will depend on its ability to maintain product quality, manage costs effectively, and strengthen its market presence in a competitive landscape.

Centenial Surgical Share Price

Live · BSE · Inception: 1995
| |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Standalone · annual

Centenial Surgical Quarterly Results

#(Fig in Cr.) Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Net Sales 12 12 14 14 12 13 13 13 15 13
Other Income 0 0 0 0 0 0 0 0 0 0
Total Income 12 12 14 14 12 13 13 14 15 13
Total Expenditure 11 11 12 13 11 11 12 12 13 12
Operating Profit 1 2 2 2 1 2 1 1 2 1
Interest 1 1 1 1 0 2 0 0 0 2
Depreciation 0 0 1 1 1 1 1 1 1 1
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 0 0 0 0 -1 -1 -0 -0 0 -2
Provision for Tax 0 -0 0 0 0 -0 0 0 0 0
Profit After Tax 0 0 0 0 -1 -1 -0 -0 0 -2
Adjustments 0 0 -0 0 0 -0 0 -0 0 0
Profit After Adjustments 0 0 0 0 -1 -1 -0 -0 0 -2
Adjusted Earnings Per Share 0.8 0.5 0.8 0.3 -2.3 -3.2 -0.1 -0 0.4 -6.3

Centenial Surgical Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 52 51 53 53 56 56 37 44 53 51 54 54
Other Income 0 0 0 0 0 0 0 0 0 0 0 0
Total Income 52 51 53 53 56 56 37 44 53 51 54 55
Total Expenditure 47 47 48 48 51 50 32 40 48 46 47 49
Operating Profit 5 5 5 5 5 6 5 5 5 5 7 5
Interest 2 2 2 2 2 2 2 2 2 3 4 2
Depreciation 1 1 1 1 1 2 2 2 1 1 4 4
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 3 2 3 2 3 2 2 1 1 1 -2 -2
Provision for Tax 1 1 1 1 1 1 1 0 1 0 -0 0
Profit After Tax 2 2 2 2 2 1 1 1 1 1 -1 -2
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 2 2 2 2 2 1 1 1 1 1 -1 -2
Adjusted Earnings Per Share 5.2 4.3 4.7 4.2 5.5 3.6 2.6 1.7 2.4 3.1 -4 -6

Centenial Surgical Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 21 23 24 26 28 29 30 30 31 32 31
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 1 1 1 1 1 1 1 0 0 0 0
Other Non-Current Liabilities 2 2 2 2 1 9 8 7 6 14 22
Total Current Liabilities 31 27 28 26 26 31 32 24 29 33 32
Total Liabilities 55 53 56 55 57 69 70 61 66 79 85
Fixed Assets 4 4 4 4 4 10 9 8 6 13 20
Other Non-Current Assets 0 0 0 0 0 1 0 0 1 1 2
Total Current Assets 51 49 52 51 52 58 61 53 59 65 63
Total Assets 55 53 56 55 57 69 70 61 66 79 85

Centenial Surgical Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 1 2 1 1 1 0 1 1 0 0 1
Cash Flow from Operating Activities 0 -2 -0 2 2 2 2 5 1 6 17
Cash Flow from Investing Activities -0 -0 -2 -1 -1 -1 -1 -0 -0 -8 -12
Cash Flow from Financing Activities 1 1 2 -1 -1 -0 -1 -5 -1 2 -6
Net Cash Inflow / Outflow 1 -1 -0 0 -1 0 -0 -0 0 0 -0
Closing Cash & Cash Equivalent 2 1 1 1 0 1 1 0 0 1 0

Centenial Surgical Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 5.25 4.28 4.71 4.23 5.53 3.55 2.64 1.72 2.43 3.11 -4.01
CEPS(Rs) 7.53 6.13 6.32 5.87 7.43 7.81 6.89 5.9 5.99 6.91 7.65
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 53.29 57.57 62.28 66.51 72.03 73.55 76.19 77.91 80.33 83.44 79.43
Core EBITDA Margin(%) 9.05 8.69 9.08 8.46 9.44 10.65 13.83 10.09 8.36 10.06 11.99
EBIT Margin(%) 8.28 7.48 8.17 7.44 8.44 8.02 9.88 6.76 6.13 7.6 4.27
Pre Tax Margin(%) 5.27 4.35 4.82 4.58 5.07 3.87 4.14 2.42 2.78 2.49 -3.02
PAT Margin (%) 3.48 2.87 3.25 2.92 3.6 2.33 2.6 1.41 1.68 2.22 -2.73
Cash Profit Margin (%) 4.99 4.11 4.36 4.06 4.84 5.12 6.8 4.85 4.15 4.93 5.22
ROA(%) 3.64 2.89 3.17 2.77 3.6 2.06 1.38 0.95 1.39 1.56 -1.79
ROE(%) 10.37 7.72 7.86 6.56 7.98 4.88 3.52 2.23 3.07 3.8 -4.93
ROCE(%) 14.22 11.74 14.02 14.84 16.75 12.64 8.65 7.27 8.02 8.87 5.09
Receivable days 127.54 128.23 129.93 128.11 126.33 144.58 226.09 172.23 139.05 140.46 126.86
Inventory Days 135.98 153.42 183.5 208.31 196.63 203.52 338.14 281.38 240.91 284.36 293.26
Payable days 249.01 221.97 136.29 138.3 125.05 156.01 406.55 177.73 189.11 234.8 178.88
PER(x) 9.91 15.85 15.64 19.4 8.94 9.8 16.22 35.34 25.4 29.38 0
Price/Book(x) 0.98 1.18 1.18 1.23 0.69 0.47 0.56 0.78 0.77 1.09 1.38
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 0.57 0.71 0.52 0.57 0.34 0.44 0.77 0.7 0.61 0.92 0.97
EV/Core EBITDA(x) 5.44 7.74 5.56 6.64 3.48 4.11 5.49 6.89 7.08 8.92 7.98
Net Sales Growth(%) 1.49 -0.6 2.7 -0.18 6.27 -0.79 -33.59 20.29 18.52 -2.78 4.55
EBIT Growth(%) 12.34 -10.6 6.01 -9.05 20.47 -5.68 -18.21 -17.74 7.59 20.42 -41.27
PAT Growth(%) 6.91 -18.5 10.13 -10.28 30.76 -35.74 -25.78 -34.8 41.27 28.04 -229.03
EPS Growth(%) 6.91 -18.5 10.13 -10.28 30.76 -35.74 -25.78 -34.8 41.27 28.04 -229.03
Debt/Equity(x) 0.58 0.58 0.05 0.05 0.04 0.44 0.46 0.31 0.32 0.45 0.4
Current Ratio(x) 1.65 1.83 1.83 1.94 2 1.87 1.92 2.2 2.04 1.99 1.98
Quick Ratio(x) 0.93 0.94 0.78 0.78 0.86 0.83 0.77 0.87 0.76 0.69 0.61
Interest Cover(x) 2.75 2.39 2.44 2.59 2.5 1.93 1.72 1.56 1.83 1.49 0.59
Total Debt/Mcap(x) 0.65 0.53 0.04 0.04 0.07 1 0.86 0.42 0.44 0.43 0.31

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +6% +7% -1% 0%
Operating Profit CAGR +40% +12% +3% +3%
PAT CAGR -200% 0% 0% 0%
Share Price CAGR -40% +7% +9% +4%
ROE Average -5% +1% +2% +5%
ROCE Average +5% +7% +8% +11%

Centenial Surgical Shareholding Pattern

Latest · Mar 2026
100% held
Promoters 46.89 %
FII 0 %
DII (MF + Insurance) 0 %
Public (retail) 53.11 %
# Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Promoter 46.8946.8946.8946.8946.8946.8946.8946.8946.8946.89
FII 0000000000
DII 0000000000
Public 53.1153.1153.1153.1153.1153.1153.1153.1153.1153.11
Others 0000000000
Total 100100100100100100100100100100

Centenial Surgical Peer Comparison

Medical Equipment/Supplies/Accessories Edit Columns

Centenial Surgical Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Centenial Surgical Pros & Cons

Pros

  • Debtor days have improved from 234.8 to 178.88days.
  • Company is almost debt free.

Cons

  • Promoter holding is low: 46.89%.
  • Company has a low return on equity of 1% over the last 3 years.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp